186 related articles for article (PubMed ID: 34228889)
1. Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation.
De B; Venkatesan AM; Msaouel P; Ghia AJ; Li J; Yeboa DN; Nguyen QN; Bishop AJ; Jonasch E; Shah AY; Campbell MT; Wang J; Zurita-Saavedra AJ; Karam JA; Wood CG; Matin SF; Tannir NM; Tang C
BJU Int; 2022 May; 129(5):610-620. PubMed ID: 34228889
[TBL] [Abstract][Full Text] [Related]
2. Stereotactic Radiotherapy for Oligoprogression in Metastatic Renal Cell Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy: A Phase 2 Prospective Multicenter Study.
Cheung P; Patel S; North SA; Sahgal A; Chu W; Soliman H; Ahmad B; Winquist E; Niazi T; Patenaude F; Lim G; Heng DYC; Dubey A; Czaykowski P; Wong RKS; Swaminath A; Morgan SC; Mangat R; Keshavarzi S; Bjarnason GA
Eur Urol; 2021 Dec; 80(6):693-700. PubMed ID: 34399998
[TBL] [Abstract][Full Text] [Related]
3. Oligo metastatic renal cell carcinoma: stereotactic body radiation therapy, if, when and how?
Marvaso G; Corrao G; Oneta O; Pepa M; Zaffaroni M; Corso F; Gandini S; Cecconi A; Zerini D; Mazzola GC; Augugliaro M; Cossu Rocca M; Verri E; Cattani F; La Fauci F; Bergamaschi L; Luzzago S; Mistretta AF; Musi G; Nolè F; De Cobelli O; Orecchia R; Jereczek-Fossa BA
Clin Transl Oncol; 2021 Aug; 23(8):1717-1726. PubMed ID: 33687659
[TBL] [Abstract][Full Text] [Related]
4. Phase II Trial of Stereotactic Ablative Radiation for Oligoprogressive Metastatic Kidney Cancer.
Hannan R; Christensen M; Hammers H; Christie A; Paulman B; Lin D; Garant A; Arafat W; Courtney K; Bowman I; Cole S; Sher D; Ahn C; Choy H; Timmerman R; Brugarolas J
Eur Urol Oncol; 2022 Apr; 5(2):216-224. PubMed ID: 34986993
[TBL] [Abstract][Full Text] [Related]
5. Effect of Switching Systemic Treatment After Stereotactic Radiosurgery for Oligoprogressive, Metastatic Renal Cell Carcinoma.
Barata PC; Mendiratta P; Kotecha R; Gopalakrishnan D; Juloori A; Chao ST; Koshkin V; Ornstein M; Gilligan TD; Wood LS; Rini BI; Angelov L; Garcia JA
Clin Genitourin Cancer; 2018 Oct; 16(5):413-419.e1. PubMed ID: 30172552
[TBL] [Abstract][Full Text] [Related]
6. Surgery for thoracic oligoprogression in metastatic renal cell cancer in the era of new systemic therapies.
Le UT; Passlick B; Schmid S
J Thorac Dis; 2023 Mar; 15(3):1133-1141. PubMed ID: 37065601
[TBL] [Abstract][Full Text] [Related]
7. Stereotactic Radiotherapy for the Treatment of Patients With Oligo-progressive Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor: Data From the Real World.
Gebbia V; Girlando A; DI Grazia A; Fazio I; Borsellino N; Piazza D; Serretta V; Pergolizzi S; Pontoriero A; Firenze A; Valerio MR
Anticancer Res; 2020 Dec; 40(12):7037-7043. PubMed ID: 33288600
[TBL] [Abstract][Full Text] [Related]
8. The Emerging Role of Extracranial Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma: A Systematic Review.
Le Guevelou J; Sargos P; Siva S; Ploussard G; Ost P; Gillessen S; Zilli T
Eur Urol Focus; 2023 Jan; 9(1):114-124. PubMed ID: 36151031
[TBL] [Abstract][Full Text] [Related]
9. Stereotactic radiation therapy in the strategy of treatment of metastatic renal cell carcinoma: A study of the Getug group.
Meyer E; Pasquier D; Bernadou G; Calais G; Maroun P; Bossi A; Theodore C; Albiges L; Stefan D; de Crevoisier R; Hennequin C; Lagrange JL; Grellard JM; Clarisse B; Licaj I; Habrand JL; Carrie C; Joly F
Eur J Cancer; 2018 Jul; 98():38-47. PubMed ID: 29864737
[TBL] [Abstract][Full Text] [Related]
10. Stereotactic body radiotherapy for oligoprogressive lesions in metastatic castration-resistant prostate cancer patients during abiraterone/enzalutamide treatment.
Onal C; Kose F; Ozyigit G; Aksoy S; Oymak E; Muallaoglu S; Guler OC; Tilki B; Hurmuz P; Akyol F
Prostate; 2021 Jun; 81(9):543-552. PubMed ID: 33905131
[TBL] [Abstract][Full Text] [Related]
11. The impact of stereotactic ablative radiotherapy on oligoprogressive metastases from renal cell carcinoma.
Franzese C; Marini B; Baldaccini D; Badalamenti M; Navarria P; Bellu L; Franceschini D; Comito T; Clerici E; Teriaca MA; Massaro M; Di Cristina L; Lo Faro L; Tomatis S; Scorsetti M
J Cancer Res Clin Oncol; 2023 Jul; 149(8):4411-4417. PubMed ID: 36109401
[TBL] [Abstract][Full Text] [Related]
12. Spine stereotactic radiosurgery with concurrent tyrosine kinase inhibitors for metastatic renal cell carcinoma.
Miller JA; Balagamwala EH; Angelov L; Suh JH; Rini B; Garcia JA; Ahluwalia M; Chao ST
J Neurosurg Spine; 2016 Dec; 25(6):766-774. PubMed ID: 27391397
[TBL] [Abstract][Full Text] [Related]
13. Is stereotactic body radiotherapy an effective treatment in metastatic lung cancer with oligoprogressive disease?
Aquilano M; Loi M; Visani L; Livi L; Nuyttens JJ
Acta Oncol; 2023 Mar; 62(3):298-304. PubMed ID: 36905644
[TBL] [Abstract][Full Text] [Related]
14. Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial.
Tang C; Msaouel P; Hara K; Choi H; Le V; Shah AY; Wang J; Jonasch E; Choi S; Nguyen QN; Das P; Prajapati S; Yu Z; Khan K; Powell S; Murthy R; Sircar K; Tannir NM
Lancet Oncol; 2021 Dec; 22(12):1732-1739. PubMed ID: 34717797
[TBL] [Abstract][Full Text] [Related]
15. The role of surgery in the treatment of oligoprogression after systemic treatment for advanced non-small cell lung cancer.
Joosten PJM; de Langen AJ; van der Noort V; Monkhorst K; Klomp HM; Veenhof AAFA; Dickhoff C; Smit EF; Hartemink KJ
Lung Cancer; 2021 Nov; 161():141-151. PubMed ID: 34600405
[TBL] [Abstract][Full Text] [Related]
16. The role of stereotactic body radiation therapy and its integration with systemic therapies in metastatic kidney cancer: a multicenter study on behalf of the AIRO (Italian Association of Radiotherapy and Clinical Oncology) genitourinary study group.
Franzese C; Marvaso G; Francolini G; Borghetti P; Trodella LE; Sepulcri M; Matrone F; Nicosia L; Timon G; Ognibene L; Vinciguerra A; Alongi F; Bortolus R; Corti L; Ramella S; Magrini SM; Livi L; Jereczek-Fossa BA; Scorsetti M; Arcangeli S
Clin Exp Metastasis; 2021 Dec; 38(6):527-537. PubMed ID: 34748125
[TBL] [Abstract][Full Text] [Related]
17. Local Therapy for Oligoprogressive Disease in Patients With Advanced Stage Non-small-cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation.
Qiu B; Liang Y; Li Q; Liu G; Wang F; Chen Z; Liu M; Zhao M; Liu H
Clin Lung Cancer; 2017 Nov; 18(6):e369-e373. PubMed ID: 28465010
[TBL] [Abstract][Full Text] [Related]
18. Treatment Outcome of metastatic lesions from renal cell carcinoma underGoing Extra-cranial stereotactic body radioTHERapy: The together retrospective study.
Buti S; Bersanelli M; Viansone A; Leonetti A; Masini C; Ratta R; Procopio G; Maines F; Iacovelli R; Ciccarese C; Vitale MG; De Giorgi U; Mucciarini C; Maruzzo M; Prati G; Lattanzi E; Ciammella P; Bruni A; Andreani S; D'Abbiero N
Cancer Treat Res Commun; 2020; 22():100161. PubMed ID: 31677494
[TBL] [Abstract][Full Text] [Related]
19. Stereotactic Ablative Radiation Therapy for Oligoprogressive Renal Cell Carcinoma.
Schoenhals JE; Mohamad O; Christie A; Zhang Y; Li D; Singla N; Bowman I; Arafat W; Hammers H; Courtney K; Cole S; Bagrodia A; Margulis V; Desai N; Garant A; Choy H; Timmerman R; Brugarolas J; Hannan R
Adv Radiat Oncol; 2021; 6(5):100692. PubMed ID: 34646963
[TBL] [Abstract][Full Text] [Related]
20. The role of stereotactic body radiotherapy in switching systemic therapy for patients with extracranial oligometastatic renal cell carcinoma.
Onal C; Hurmuz P; Guler OC; Yavas G; Tilki B; Oymak E; Yavas C; Ozyigit G
Clin Transl Oncol; 2022 Aug; 24(8):1533-1541. PubMed ID: 35119653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]